Scarica l'app Stockscreener
3.67
3.09%
0.11
Dopo l'orario di chiusura:
3.65
-0.02
-0.54%
Precedente Chiudi:
$3.56
Aprire:
$3.6
Volume 24 ore:
1.05M
Relative Volume:
0.72
Capitalizzazione di mercato:
$334.62M
Reddito:
$58.36M
Utile/perdita netta:
$-25.72M
Rapporto P/E:
-8.1556
EPS:
-0.45
Flusso di cassa netto:
$-24.91M
1 W Prestazione:
+0.27%
1M Prestazione:
-23.70%
6M Prestazione:
+51.65%
1 anno Prestazione:
+82.59%
Intervallo 1D:
$3.55
$3.79
Intervallo di 1 settimana:
$3.36
$3.79
Portata 52W:
$1.98
$6.23
Aquestive Therapeutics Inc Stock (AQST) Company Profile
Nome
Aquestive Therapeutics Inc
Settore
Telefono
908-941-1900
Indirizzo
30 TECHNOLOGY DRIVE, WARREN, NJ
Confronta AQST con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AQST
Aquestive Therapeutics Inc
|
3.67 | 334.62M | 58.36M | -25.72M | -24.91M | -0.3641 |
|
ZTS
Zoetis Inc
|
162.61 | 73.36B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.44 | 42.68B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.25 | 42.01B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.30 | 24.13B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.42 | 14.82B | 15.05B | -883.30M | 1.89B | -0.74 |
Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-05-10 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Piper Sandler | Overweight |
| 2024-03-28 | Iniziato | Raymond James | Outperform |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2019-04-22 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-03 | Iniziato | Lake Street | Buy |
| 2018-08-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2018-08-20 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aquestive Therapeutics Inc Borsa (AQST) Ultime notizie
What Analysts Were Expecting After Aquestive Therapeutics Inc (NASDAQ: AQST) rose 4.21% - Stocks Register
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Sold by Stifel Financial Corp - Defense World
State Street Corp Has $7.45 Million Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
State Street Corp Purchases 512,682 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Stifel Financial Corp Sells 301,538 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics’ (AQST) “Buy” Rating Reiterated at HC Wainwright - Defense World
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - MSN
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Rating of “Buy” from Analysts - Defense World
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Aquestive shares reiterated at Buy by analyst as FDA grants ODE to Libervant - Investing.com Canada
Aquestive Therapeutics (NASDAQ:AQST) Receives "Buy" Rating from HC Wainwright - MarketBeat
Analysts Set Expectations for AQST FY2024 Earnings - Defense World
Wellington Management Group LLP Invests $922,000 in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics Gains FDA Orphan Drug Exclusivity for Pediatric Seizure Treatment - Yahoo Finance
Aquestive Therapeutics Receives U.S. FDA Orphan Drug - GlobeNewswire
Cantor Fitzgerald Forecasts AQST FY2024 Earnings - MarketBeat
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25% - Simply Wall St
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Bought by BNP Paribas Financial Markets - Defense World
Cantor Fitzgerald Initiates Coverage on Aquestive Therapeutics (NASDAQ:AQST) - Defense World
Charles Schwab Investment Management Inc. Purchases 9,268 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - Defense World
Aquestive Therapeutics' SWOT analysis: stock poised for growth with innovative epinephrine delivery - Investing.com Canada
Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside - Yahoo Finance UK
Aquestive Therapeutics (NASDAQ:AQST) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Aquestive Therapeutics stock initiated at Overweight by Fitzgerald, eyes strong 2025 catalysts - Investing.com UK
Aquestive Therapeutics' (NASDAQ:AQST) investors will be pleased with their favorable 88% return over the last year - Yahoo Finance
Cantor Fitzgerald Initiates Coverage of Aquestive Therapeutics (AQST) with Overweight Recommendation - MSN
Aquestive Therapeutics (NASDAQ:AQST) shareholders have earned a 88% return over the last year - Simply Wall St
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth - Investing.com Nigeria
Aquestive Therapeutics' SWOT analysis: oral epinephrine stock poised for growth By Investing.com - Investing.com South Africa
Oral Thin Films Market Growth in Future Scope 2024-2031 | - openPR
Verition Fund Management LLC Takes $995,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics confirms FDA nod for Anaphylm trial By Investing.com - Investing.com Canada
Aquestive Therapeutics confirms FDA nod for Anaphylm trial - Investing.com
Aquestive Therapeutics Gains FDA Support for Anaphylm - TipRanks
Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm™ (epinephrine) Sublingual Film - The Manila Times
Aquestive Therapeutics Announces Positive FDA Feedback and - GlobeNewswire
Aquestive's Oral Epinephrine Treatment Advances After Key FDA Feedback for NDA Filing - StockTitan
Aquestive therapeutics COO Jung Cassie sells $214 in stock By Investing.com - Investing.com Nigeria
Aquestive therapeutics COO Jung Cassie sells $214 in stock - Investing.com
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update - MarketBeat
GSA Capital Partners LLP Acquires 115,223 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? - Yahoo Finance
ARMISTICE CAPITAL, LLC Acquires New Stake in Aquestive Therapeutics Inc - GuruFocus.com
Chartwell Investment Partners LLC Buys New Holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) - MarketBeat
Aquestive Therapeutics, Inc. Announces Board and Committee Changes - Marketscreener.com
Aquestive Therapeutics Inc Azioni (AQST) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.50%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):